DexCom
DXCM · NASDAQ · Healthcare
$87.73
$1.41 (-1.61%) today
Market Cap
$33.11B
24h Volume
$318.0M
P/E Ratio
34.7
52w High
$92.34
52w Low
$54.84
Est. AI Revenue
18%
7-Day Sparkline (Static)
Company facts
Performance
About DexCom
DexCom makes continuous glucose monitors, wearable sensors that track blood sugar in real time for people with diabetes. It earns revenue from sensor sales, driven by patient adoption and insurance reimbursement, and its devices pair with apps that turn readings into guidance.
AI shapes that guidance layer. Its glucose prediction algorithms warn users where their levels are heading, Stelo AI Analytics adds the same intelligence to its Stelo product line, Clarity AI Reports summarize patterns for patients and doctors, and smart insulin dosing AI helps inform dosing decisions.
Founded in 1999 and headquartered in San Diego, California, DexCom trades on the NASDAQ and employs roughly 11,000 people.
DexCom in the AI buildout
DexCom sits at the periphery of the AI Healthcare layer of the buildout. AI algorithms make its glucose data more useful, powering prediction, pattern recognition, and dosing insights. But the business runs on sensor adoption and reimbursement decisions, not AI demand, so AI is a product feature rather than a growth driver. Supercycle assigns it an AI Exposure Score of 8 out of 100.
DXCM is tracked in AI Healthcare, rated Peripheral on the AI Exposure leaderboard.
By the numbers
52-week range
DXCM trades at $87.73, 88% of the way up its 52-week range of $54.84 to $92.34.
Market cap
Market capitalization is $33.11B, with an AI Exposure Score of 8 out of 100.
Valuation vs peers
Its P/E ratio of 34.7 is above the AI Healthcare category median of 29.6.
Next earnings
DexCom is next expected to report earnings on October 29, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does DexCom do?
DexCom makes continuous glucose monitors, wearable sensors that track blood sugar in real time for people managing diabetes. Revenue comes from sensor sales supported by insurance reimbursement.
How is DexCom exposed to AI?
AI powers glucose prediction, pattern recognition, and dosing insights in its apps, but revenue depends on sensor adoption and reimbursement. Supercycle rates it an AI Exposure Score of 8 out of 100.
What are DexCom's main AI products?
Dexcom AI Glucose Prediction for forecasting blood sugar trends, Stelo AI Analytics, Clarity AI Reports for summarizing patterns, and smart insulin dosing AI that helps inform dosing decisions.
Is DXCM a pure play AI stock?
No. DexCom is a medical device company where AI enhances the product experience. Its AI Exposure Score of 8 out of 100 places it near the low end of Supercycle's rankings.
Where is DexCom based and who leads it?
DexCom is headquartered in San Diego, California, and is led by CEO Jacob Steven Leach. Founded in 1999, it employs roughly 11,000 people and trades on the NASDAQ.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.